Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Restoring Immune Balance: Therapeutic Approaches and Future Directions in Immune Homeostasis
Description
The discussion focuses on the therapeutic approaches aimed at restoring immune tolerance in autoimmune diseases, emphasizing the complexity of treatment responses influenced by various factors, such as genetic and demographic differences. The primary therapeutic strategies include the use of regulatory T cells (Tregs), utilizing interleukin-2 (IL-2) in different doses, and innovative methods such as CAR T-cell therapy and metabolic approaches. Recent studies highlight the effectiveness of low-dose IL-2 in regulating immune responses, particularly in conditions like lupus and other autoimmune disorders, while also noting the necessity for precise patient stratification and molecular profiling in clinical trials. Notably, the use of IL-2 has demonstrated promising results in lupus, leading to improvements without exacerbating existing conditions. Additionally, discussions cover the exploration of CAR T-reg cells that induce immune tolerance, opening avenues for future treatments, especially in dermatological conditions. The presentation underscores the importance of an interdisciplinary approach to personalize medicine effectively, aiming to restore immune homeostasis and enhance treatment efficacy in diverse patient populations.
View moreConclusions
- The restoration of immune tolerance is a primary therapeutic goal in autoimmune diseases.
- Low-dose IL-2 therapy may induce regulatory T cells to regulate immune responses in conditions like lupus.
- Different strategies, such as CAR Treg cells and metabolic approaches, can potentially enhance immune tolerance.
- Treg-based therapies show promise in treating various autoimmune skin diseases through mechanisms that modulate immune responses.
- Clinical trials indicate low-dose IL-2 is effective in improving disease outcomes, with manageable side effects.
- Addressing the heterogeneity of autoimmune diseases is vital for personalized treatment approaches, emphasizing the importance of molecular profiling.
- Novel therapies, including IL-2 muteins and targeted CAR T therapies, are being evaluated for their ability to restore immune balance in patients.
- Metabolomic studies and treatments like gluconolactone represent innovative avenues for enhancing Treg function and immune regulation.
- Kolios A and Behrendt M, 2017
- Sharabi A et al ., Nat Rev Drug Discov, 2018
- Burmester GR et al ., Nat Rev Rheumatol, 2017
- Yuan Y and Kolios AGA et al ., Trends Mol Med, 2022
- Kolios AGA, Tsokos GC, Klatzmann D, Nat Rev Rheumatol, 2021
- Lipser D and colleagues, Clinic Rev Allerg Immunol (2017) 53:291-305
- Koreth J et al ., N Engl J Med, 2011
- Silverberg JI et al ., Nat Comm, 2024
- Cheever A et al ., FIMMU, 2024
- Müller F et al ., N Engl J Med, 2024
- Kolios AGA and Li W et al ., Science Translational Medicine, 2025
- Wei Li et al ., Sci Transl Med, DOI:10.1126/scitranslmed.adp4447
- Kalaiselvi et al ., in revision
- Lerner G. et al ., in revision